CoronaryAtlas logo
CoronaryAtlas
Fibrinogen Beta Chain
Pathway / Coagulation & thrombus formation

Fibrinogen Beta Chain

FGBprotein

Fibrinogen polymerizes into fibrin scaffolding the occlusive coronary thrombus and amplifies platelet aggregation.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleFibrinogen anchor; structural component of fibrin clot; platelet aggregation ligand; thrombus formation.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates5
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000171564

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
67
A — assay feasibility
96
E — evidence strength
60
T1DI (composite)
14
Specificity differential (R−C)-51.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 1/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 17 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Platelet-poor plasma
Collection tube
Sodium citrate 3.2% (light blue-top)
Method / principle
Clauss clotting-time assay
Reagent / substrate
Excess thrombin reagent; clot-time inversely proportional to fibrinogen
Platform
Coagulation analyzer
Turnaround · availability
STAT · Universal

Literature evidence(25)